These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1584 related articles for article (PubMed ID: 29301960)

  • 1. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
    Miao D; Margolis CA; Gao W; Voss MH; Li W; Martini DJ; Norton C; Bossé D; Wankowicz SM; Cullen D; Horak C; Wind-Rotolo M; Tracy A; Giannakis M; Hodi FS; Drake CG; Ball MW; Allaf ME; Snyder A; Hellmann MD; Ho T; Motzer RJ; Signoretti S; Kaelin WG; Choueiri TK; Van Allen EM
    Science; 2018 Feb; 359(6377):801-806. PubMed ID: 29301960
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.
    Hakimi AA; Attalla K; DiNatale RG; Ostrovnaya I; Flynn J; Blum KA; Ged Y; Hoen D; Kendall SM; Reznik E; Bowman A; Hwee J; Fong CJ; Kuo F; Voss MH; Chan TA; Motzer RJ
    Nat Commun; 2020 Aug; 11(1):4168. PubMed ID: 32820162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
    Panda A; de Cubas AA; Stein M; Riedlinger G; Kra J; Mayer T; Smith CC; Vincent BG; Serody JS; Beckermann KE; Ganesan S; Bhanot G; Rathmell WK
    JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
    Hagiwara M; Fushimi A; Matsumoto K; Oya M
    Eur Urol; 2022 Feb; 81(2):145-148. PubMed ID: 34627641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
    Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
    Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on immunotherapy for renal cancer.
    Canales Rojas R
    Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
    Kawakami F; Sircar K; Rodriguez-Canales J; Fellman BM; Urbauer DL; Tamboli P; Tannir NM; Jonasch E; Wistuba II; Wood CG; Karam JA
    Cancer; 2017 Dec; 123(24):4823-4831. PubMed ID: 28832979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
    JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
    Zhu XR; Zheng LZ
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
    Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
    Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
    Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
    Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
    Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
    Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.
    Zhu Z; Jin Y; Zhou J; Chen F; Chen M; Gao Z; Hu L; Xuan J; Li X; Song Z; Guo X
    Mol Cancer; 2024 Jul; 23(1):146. PubMed ID: 39014460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.